This review highlights the clinical impact of clopidogrel resistance in ACS patients, including increased mortality and stent thrombosis, and discusses alternative antiplatelet strategies.
Answers are grounded in this paper and cite their sources.
Clopidogrel resistance in ACS merits vigilance; leaves open standardized testing and new-agent strategies pending prospective trials.
Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of Stent Thrombosis. This review article tries to find out the causes of Clopidogrel Resistance, the main factors involving it, Laboratory evaluation of Clopidogrel Resistance. The overall incidence of Clopidogrel Resistance across the Globe & India has also been considered. The article also discusses the clinical significance of Clopidogrel Resistance & its relationship with adverse cardiovascular events. This review ends with the probable solutions to Clopidogrel Resistance & the new generation of antiplatelets which can be used for the same.
No takes yet. Share an insight, caveat, or question.
Shuvanan Ray (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: